Homology Medicines (Homology Medicines) Price-to-Tangible-Book : 0.04 (As of May. 04, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Price-to-Tangible-Book?

As of today (2024-05-04), Homology Medicines's share price is $0.9347. Homology Medicines's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $22.65. Hence, Homology Medicines's Price to Tangible Book Ratio of today is 0.04.

The historical rank and industry rank for Homology Medicines's Price-to-Tangible-Book or its related term are showing as below:

FIXX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.04 Med: 2.07 Max: 4.25
Current: 0.04

During the past 8 years, Homology Medicines's highest Price to Tangible Book Ratio was 4.25. The lowest was 0.04. And the median was 2.07.

FIXX's Price-to-Tangible-Book is ranked better than
99.92% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs FIXX: 0.04

A closely related ratio is called PB Ratio. As of today, Homology Medicines's share price is $0.9347. Homology Medicines's Book Value per Sharefor the quarter that ended in Dec. 2023 was $22.65. Hence, Homology Medicines's P/B Ratio of today is 0.04.

Homology Medicines Price-to-Tangible-Book Historical Data

The historical data trend for Homology Medicines's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Price-to-Tangible-Book Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.61

2.90

1.23

0.41

0.48

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															0.41	0.39	0.43	0.77	0.48

Competitive Comparison of Homology Medicines's Price-to-Tangible-Book

For the Biotechnology subindustry, Homology Medicines's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Price-to-Tangible-Book falls into.

Homology Medicines Price-to-Tangible-Book Calculation

Homology Medicines's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.9347	/	22.646
	=	0.04

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Homology Medicines Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (Homology Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Executives

Paul Alloway	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour	officer: Chief Scientific Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum	officer: Chief Commercial Officer	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith	officer: CFO, Treasurer & Secretary	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos	director, officer: President & CEO	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: *Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty	officer: Chief Operating Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109